Versant Venture Management, LLC Long-Term Concentrated

CIK: 0001560009 · Show all filings

Period: Q1 2016 (← Previous) (Next →)

Filing Date: Apr 25, 2016

Total Value ($000): $138,515,846 (100.0% shares, 0.0% debt)

Holdings (7)

GKOS Glaukos Corporation 38.2%

Value ($000) $52,876,871 Shares 3,136,232 Est. Cost $30.09 Unrealized -42.4%

— Five Prime Therapeutics, Inc. 32.0%

Value ($000) $44,374,135 Shares 1,092,152 Est. Cost $27000.00 Unrealized —

OCUL Ocular Therapeutix, Inc. 15.4%

Value ($000) $21,400,609 Shares 2,215,384 Est. Cost $20.09 Unrealized -62.3%

— Clovis Oncology, Inc. 5.6%

Value ($000) $7,822,387 Shares 407,416 Est. Cost $56000.00 Unrealized —

— Biotie Therapies Corp. 5.1%

Value ($000) $7,090,254 Shares 268,672 Est. Cost $19970.00 Unrealized —

— Achaogen, Inc. 2.6%

Value ($000) $3,535,979 Shares 1,281,152 Est. Cost $13050.00 Unrealized —

— CymaBay Therapeutics, Inc. 1.0%

Value ($000) $1,415,611 Shares 1,048,601 Est. Cost $9830.00 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
GKOS	Glaukos Corporation	3,136,232	$52,876,871	38.2%	$30.09	-42.4%	Common Stock	377322102
—	Five Prime Therapeutics, Inc.	1,092,152	$44,374,135	32.0%	$27000.00	—	Common Stock	33830X104
OCUL	Ocular Therapeutix, Inc.	2,215,384	$21,400,609	15.4%	$20.09	-62.3%	Common Stock	67576A100
—	Clovis Oncology, Inc.	407,416	$7,822,387	5.6%	$56000.00	—	Common Stock	189464100
—	Biotie Therapies Corp.	268,672	$7,090,254	5.1%	$19970.00	—	ADS	09074D103
—	Achaogen, Inc.	1,281,152	$3,535,979	2.6%	$13050.00	—	Common Stock	004449104
—	CymaBay Therapeutics, Inc.	1,048,601	$1,415,611	1.0%	$9830.00	—	Common Stock	23257D103